The Paseíco de la Mama solidarity initiative has enabled VHIO’s Breast Cancer Group to carry out numerous research projects over…
Breast Cancer Group
Recently published in The New England Journal of Medicine1 results of a phase 3, double-blind, randomized trial show that the…
The results of the SOLTI-2103 VALENTINE clinical trial demonstrate that the antibody drug conjugate (ADC) patritumab deruxtecan at the standard…
• Endocrine therapy is a type of cancer treatment that slows or halts the growth of hormone-sensitive cancers and is…
Recently published in The New England Journal of Medicine, results from the phase 3, multicenter DESTINY-06 clinical trial show that…
Based on results from the CAPITello-291 phase III study, co-led by VHIO’s Mafalda Oliveira, Senior Medical Oncologist at Vall d’Hebron…
Results from an international Phase IIa study point to the promise of adding bispecific HER2-targeted antibody zanidatamab to the combination…
Researchers at the Vall d’Hebron Institute of Oncology (VHIO), part of the Vall d’Hebron Campus, have found that breast milk…
Approximately 70% of advanced breast cancers are hormone receptor-positive (HR+)/HER2-negative. Hormone therapies are widely used for the treatment of patients…
Presented at the 2023 ESMO Breast Cancer Annual Congress, 11-13 May in Berlin, final results of the SOLTI-TOT-HER3 window of…
